Actively Recruiting
Target of Suv420h1/2 in Hepatocytes
Led by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Updated on 2026-03-27
260
Participants Needed
1
Research Sites
217 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Nonalcoholic fatty liver disease (NAFLD) is globally the leading cause of liver disease and frequently progresses to cirrhosis and liver cancer. The identification of effective drugs is the main unmet clinical need. Changes in liver histones methylation accompanies the development and progression of NAFLD. Our preliminary data demonstrate that inactivation of the methyltransferases SUV420H1/2 in hepatocytes protects mice against NAFLD. In this project we propose to examine the relevance of these findings by evaluating the impact of genetic deletion of hepatic SUV420H1/2 in mice fed a steatogenic diet. To further evaluate the potential for clinical translation of these results, we will next 1) evaluate the expression of SUV420H1/2 in human liver transcriptomic data and 2) analyze the impact of genetic variations on disease outcomes in population-based cohorts; 3) test an innovative therapeutic approach based on hepatocyte-targeted antisense oligonucleotides downregulating SUV420H1/2 in human liver organoids/assembloids.
CONDITIONS
Official Title
Target of Suv420h1/2 in Hepatocytes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Subjects aged over 18 years
- Subjects who have already consented to genetic analysis and whose samples and data were collected in the SERENA, REASON, or MAFALDA studies
- Subjects who have given consent to participate in this study
- For SERENA study: diagnosis of NAFLD, age between 45 and 75 years, and either F3-F4 fibrosis or cirrhosis evidence, family history of primary liver cancer or rare mutation carriers, or male with type 2 diabetes or obesity carrying specific genetic variants
- For REASON study: patients over 18 who had liver biopsy for suspected NASH or liver surgery including biopsies or explants
- For MAFALDA study: patients undergoing bariatric surgery for grade 3 obesity or grade 2 obesity with metabolic comorbidities and no contraindication to surgery
You will not qualify if you...
- Individuals not meeting any of the inclusion criteria
- Individuals with at-risk alcohol intake over 30 g/day (men) or 20 g/day (women)
- Individuals with viral hepatitis, autoimmune hepatitis, or other liver diseases
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - Istituto di Ricovero e Cura a Carattere Scientifico di natura pubblica
Milan, Italy, 20122
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
PREVENTION
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here